Why did I seek more?
Knowing that there was a test that could help resolve an indeterminate diagnosis meant the world to me. I would do just about anything to avoid surgery and I trusted my doctor.
Real People
Knowing
Real Answers.
KAREN MELMED
Afirma Patient
This is the Age of Evidence.
Where a new definition of diagnostic truth is changing patient care as we know it. Where physicians and patients can now benefit from the evolution of healthcare and know, by design, the answers they seek.

Veracyte gives patients a clearer path for the future.

We are leading in the Age of Evidence.
our impact
The Age
of Evidence
Veracyte's genomic tests have the potential to save billions of dollars each year in unnecessary surgery costs.
Learn More >
Now Covered by Medicare
Genomic test is first to gain Medicare coverage for use in lung cancer screening and diagnosis.
learn more >
Evidence Equals Impact
Hear Veracyte CEO Bonnie Anderson discuss in a "Business Rockstars" interview how the company’s genomic tests are transforming patient care.

watch now >


latest news
news and updates
May 23, 2017
Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017

learn more >
May 18, 2017
Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis

learn more >
May 11, 2017
Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"

learn more >